Condition Center

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...

A screening of the differentially expressed genes based on the Gene Expression Omnibus database and further gene enrichment analysis indicates that the tyrosine kinase-binding protein TYROBP is a potential prognostic marker for multiple myeloma. Multiple myeloma is a refractory hematological cancer characterized by the malignant proliferation of plasma cells. The tyrosine kinase-binding protein TYROBP mediates...

Double-hit newly diagnosed multiple myeloma patients with minimal residual disease positivity have a poor prognosis compared to patients with minimal residual disease negativity, according to the results of a recent cohort study. Autologous stem cell transplantation (ASCT) is one of the novel therapeutic approaches that are beneficial for newly diagnosed multiple myeloma (NDMM) patients. The...

A random forest radiomics model achieved satisfactory diagnostic performance, and models based on joint CET1 and T2-weighted imaging demonstrated better performance than single-sequence models in differentiating spinal multiple myeloma from metastases.  Spinal metastases and spinal multiple myeloma have similar radiographic characteristics, making accurate differentiation a necessity for precision therapy.  This retrospective study established and assessed...

A new cohort study reports that soluble B-cell maturation antigen is present in the lacrimal fluid of multiple myeloma patients, with evidence of pinocytosis as the underlying mechanism contributing to the development of keratopathy in these patients. Belantamab is an anti-B-cell maturation antigen (anti-BCMA) antibody–drug conjugate approved for the pharmacological treatment of refractory multiple myeloma....

A retrospective analysis finds high-risk fluorescent in situ hybridization markers useful for stratifying real-world survival outcomes in newly diagnosed multiple myeloma patients. Interphase fluorescent in situ hybridization (iFISH) remains the standard of care for assessing prognosis in patients with newly diagnosed multiple myeloma (NDMM). There is, however, limited data regarding iFISH-based real-world survival outcomes. In...

Researchers have identified several clinical characteristics of psoriasis patients that may increase the risk of developing psoriatic arthritis.  A single-center, retrospective cohort study examined the clinical profiles of psoriasis patients to determine the precursors of psoriatic arthritis (PsA), aiming to bridge the gap between psoriasis management and the identification of psoriatic arthritis risk. The study’s...

Guselkumab, a targeted inhibitor of interleukin-23, has emerged as a promising therapy for psoriatic arthritis, offering hope for improved patient outcomes.  A prospective multicenter study aimed to shed light on the effectiveness of using guselkumab for psoriatic arthritis (PsA) management by analyzing the experiences of PsA patients over 6 months. The study also looked at...

Newly published data from a prospective cohort study indicate that diagnosing psoriatic arthritis within 12 weeks after symptom onset may represent a clinical window of opportunity for achieving minimal disease activity and disease remission.  In rheumatoid arthritis, the benefits of early treatment within 12 weeks following symptom onset are well-documented, leading to better remission rates,...